Despite the FDA approval of the company’s OraQuick in-home HIV test, OraSure Technologies of Bethlehem has reported a loss for 2012.
The company said its consolidated net loss for the year, which ended Dec. 31, was $15.1 million, or 29 cents per share compared to a net loss of $8.8 million or 19 cents in 2011.
The loss for 2012 included $9.9 million in costs associated with the OraQuick in-home HIV test.
Gross sales of the test amounted to $902,000 for the year.
Net product revenues for the year increased 6 percent primarily as a result of a full year of molecular collection system sales and higher cryosurgical systems sales. These increases were partially offset by lower sales of the company's infectious disease testing, substance abuse testing and insurance risk assessment products.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy